NS 1619

structure given in first source

Also Known As:

1-(2'-hydroxy-5'-trifluoromethylphenyl)-5-trifluoromethyl-2(3H)-benzimidazolone; NS-1619; NS1619; 2H-Benzimidazol-2-one, 1,3-dihydro-1-(2-hydroxy-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-

Networked: 64 relevant articles (12 outcomes, 8 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzimidazoles: 245
      - NS 1619: 64

Experts

1.	Hollmann, Markus W: 5 articles (04/2020 - 01/2012)
2.	Huhn, Ragnar: 5 articles (04/2020 - 01/2012)
3.	Heinen, André: 4 articles (04/2020 - 01/2012)
4.	Black, Keith L: 4 articles (08/2008 - 06/2002)
5.	Xia, Qiang: 4 articles (12/2005 - 01/2005)
6.	Behmenburg, Friederike: 3 articles (08/2017 - 08/2014)
7.	Ningaraj, Nagendra S: 3 articles (10/2009 - 06/2002)
8.	Gao, Qin: 3 articles (12/2005 - 01/2005)
9.	Armstead, W M: 3 articles (10/2001 - 01/2000)
10.	Mathes, Alexander: 2 articles (04/2020 - 04/2017)

Related Diseases

1.	Infarction (Infarctions) 01/01/2005 - "Pretreatment with mitoSlo(1) channel opener, NS1619 10 micromol/L for 10 min reduced the infarct size and LDH release, and improved the recovery of left ventricular developed pressure, left ventricular end-diastolic pressure, maximal rise/fall rate of left ventricular pressure and coronary flow during reperfusion. " 11/01/2004 - "This infarct-limiting effect of NS-1619 was associated with improvement in ventricular functional recovery after I/R. " 04/01/2017 - "NS1619 (10 μM) reduced infarct size to about the same magnitude as did the higher doses of Dex. " 01/01/2012 - "NS1619 reduced infarct size in the same concentration in both, young and aged rats (35±6%; p<0.05 vs. Con and 34±8%; p<0.05 vs. Age Con). " 11/01/2010 - "NS1619 reduced infarct size to 33 (4)% (P < 0.05 vs control). "
2.	Ischemia 08/15/2017 - "Preconditioning was induced by intraperitoneal application of NS1619 (NS, 1μg/g bw) 10min before ischemia, control animals (Con) received the vehicle. " 08/01/2014 - "In addition, NS1619 initiated cardioprotection also in the aged heart both when administered before ischemia and during early reperfusion phase. " 06/06/2011 - "Male Sprague-Dawley rats (250-300 g) were randomized into control, ischemia/reperfusion (I/R), remote ischemic preconditioning (RPC), NS1619 (a specific mitochondrial Ca(2+)-activated K(+) channel opener), and RPC+paxilline (a specific mitochondrial Ca(2+)-activated K(+) channel inhibitor) groups. " 11/01/2004 - "Adult male ICR mice were pretreated with the KCa-channel opener NS-1619 either 10 min or 24 h before 30 min of global ischemia and 60 min of reperfusion (I/R) in Langendorff mode. " 01/01/2015 - "Similarly, pretreatment with NS1619, an opener of the mitoKCa channels, for 10 min before occlusion reduced both the infarct size and arrhythmias caused by ischemia/reperfusion. "
3.	Hypoxia (Hypoxemia) 10/01/2014 - "Compared to normoxia, NS1619-induced vasodilation was significantly greater following hypoxia; however, NO-dependent vasodilation and BKCa-mediated vasodilation, in response to NS1619, were similar in the normoxic and hypoxic lungs. " 10/01/2015 - "Hypoxia-induced firing response was alleviated by pretreatment with NS1619, a selective BKCa activator. " 10/01/2014 - "To identify the effect of the benzimidazalone derivative, NS1619, on modulating pulmonary vascular tone in lungs from rats exposed to normoxia (21% FiO2) or chronic hypoxia (10% FiO2) for three weeks. " 01/24/2000 - "NS1619, a K(ca) channel agonist, induced pial dilation during hypoxia that was attenuated by 20- and 40-min but not by 5- and 10-min exposure durations. " 04/07/2022 - "In agreement, isolated NCM also presented increased apoptosis on treatment with NS1619 during hypoxia and reoxygenation, whereas IbTx reduced TUNEL-positive cells. "
4.	Reperfusion Injury 07/01/2014 - "It was previously reported that activation of BKCa channels by NS1619 could protect the cardiac muscle against ischaemia and reperfusion injury. " 01/01/2005 - "MitoSlo(1) channel activation by NS1619 protects the myocardium against ischemia and reperfusion injury by inhibiting mitochondrial permeability transition pore opening." 09/05/2016 - "A large conductance potassium (BKCa) channel opener, NS1619 (1,3-dihydro-1- [2-hydroxy-5-(trifluoromethyl) phenyl]-5-(trifluoromethyl)-2H-benzimidazole-2-one), is well known for its protective effects against ischemia-reperfusion injury; however, the exact mode of its action remains unclear. "
5.	Hemorrhagic Shock 02/01/2014 - "Bkca opener, NS1619 pretreatment has good protective effect on vascular reactivity and calcium sensitivity, which plays a good beneficial effect on hemorrhagic shock. " 02/01/2014 - "Whether the pretreatment of opener/activator of the large-conductance calcium-activated potassium channel (Bkca), NS1619, can also induce a protective effect on vascular reactivity and play a beneficial effect on subsequent hemorrhagic shock is not clear. " 02/01/2014 - "With Sprague-Dawley rats subjected to hemorrhagic shock and their isolated superior mesenteric artery, the protective effect of NS1619 (0.5, 1, 2, and 4 mg/kg) pretreatment (30 minutes before hemorrhage shock) on vascular reactivity and the underlying mechanisms were observed. " 04/01/2010 - "RyR activation by caffeine and BK(Ca) channel activation by NS1619 attenuated the restoration of vasoreactivity to NE resulting from A(3)AR stimulation by IB-MECA after hemorrhagic shock; this attenuation effect could be antagonized by a selective BK(Ca) channel blocker. " 02/01/2014 - "NS1619 pretreatment significantly improved the 72-hour survival of hemorrhagic shock rats, alleviated shock-induced decrease of vascular reactivity and calcium sensitivity, and increased the cardiac output and oxygen delivery. "

Related Drugs and Biologics

1.	Calcium
2.	Large-Conductance Calcium-Activated Potassium Channels (Maxi-K Channels)
3.	Potassium
4.	Diazoxide (Hyperstat)
5.	Atractyloside
6.	paxilline
7.	Drinking Water
8.	Fluconazole (Zonal)
9.	Superoxide Dismutase
10.	Superoxides (Superoxide)

Related Therapies and Procedures

1.	Intravenous Infusions
2.	Subcutaneous Infusions
3.	Therapeutics